Table 1.
Biological and clinical characteristics of the 51 acute myeloid leukemia (AML) patients included in the study.
| Patient characteristics | Cell morphology | Cell genetics | |||
|---|---|---|---|---|---|
| Age | FAB classificationa | Cytogeneticsb | |||
| Median (years) | 67 | M0 | 3 | Favorable | 9 |
| Range (years) | 19–87 | M1 | 15 | Intermediate | 6 |
| M2 | 7 | Normal | 23 | ||
| Gender | M3 | 3 | Adverse | 10 | |
| Females | 22 | M4 | 8 | n.d. | 3 |
| Males | 29 | M5 | 10 | ||
| n.d. | 5 | Flt3 mutations | |||
| Secondary AML | ITD | 15 | |||
| MDS | 6 | CD34 receptor | Wild type | 26 | |
| CMML | 4 | Negative (≤20%) | 14 | n.d. | 10 |
| Chemotherapy | 1 | Positive (>20%) | 32 | ||
| n.d. | 5 | NPM1 mutations | |||
| AML relapse | 4 | Insertion | 16 | ||
| Wild type | 26 | ||||
| n.d. | 9 | ||||
aNo patient was diagnosed with FAB M6 or M7.
bPatients with favorable karyotype had inv(16); t(15;17); and t(8;21). Patients with adverse karyotype had −5; −7; +8 and complex karyotype with at least three abnormalities.
n.d., not determined.